当前位置： SCI文献检索 > GYNECOLOGIC ONCOLOGY期刊下所有文献 > Failure of hexamethylmelamine as salvage therapy in ovarian epithelial adenocarcinoma resistant to combination chemotherapy.

Failure of hexamethylmelamine as salvage therapy in ovarian epithelial adenocarcinoma resistant to combination chemotherapy.

Abstract：

:Favorable responses to hexamethylmelamine (HMM) have been documented in untreated as well as in alkylating agent-resistant ovarian epithelial adenocarcinoma (OvCa). Platinum-based combination therapy for OvCa has been used since 1976. Eighteen patients with OvCa were treated with HMM as salvage therapy between February 1979 and October 1981. All patients had histologically confirmed OvCa. Eleven tumors were grade III/III and seven tumors were grade II/III. Sixteen patients had received cisplatin-based combination therapy, whereas two had received doxorubicin/cyclophosphamide because of other medical conditions. HMM was used alone in 16 patients and in combination with other drugs in two patients. The initial dose of HMM was 300 mg/m2/day X 14 days when used alone and 130 mg/m2/day X 14 days when used in combination with other drugs. Six patients were treated at a reduced initial dose because of prior marrow toxicity. Adverse effects were tolerable, with 14 patients experiencing hematologic toxicity (5 mild, 5 moderate, 3 severe, 1 life threatening) and 15 patients experiencing GI toxicity (5 mild, 7 moderate, 3 severe). Only 2 patients experienced no toxicity. No objective tumor responses were observed. Four patients had progression of tumor within 4 weeks of starting therapy and 14 patients had stable disease with a mean progression-free interval of 21 weeks. Although HMM is an active drug in untreated and alkylating agent-resistant OvCa, experience suggests that HMM at the dose and schedule tested has insignificant activity in patients who have failed cisplatin-based combination therapy.

journal_name

Gynecol Oncol

journal_title

Gynecologic oncology

authors

Stehman FB,Ehrlich CE,Callangan MF

doi

10.1016/0090-8258(84)90076-3

subject

Has Abstract

pub_date

1984-02-01 00:00:00

pages

189-95

issue

2

eissn

0090-8258

issn

1095-6859

journal_volume

17

pub_type

杂志文章

相关文献

GYNECOLOGIC ONCOLOGY文献大全
  • Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons.

    abstract：OBJECTIVE:We demonstrate the feasibility of detecting EC by combining minimally-invasive specimen collection techniques with sensitive molecular testing. METHODS:Prior to hysterectomy for EC or benign indications, women collected vaginal pool samples with intravaginal tampons and underwent endometrial brushing. Specim...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2015.01.552

    authors： Bakkum-Gamez JN,Wentzensen N,Maurer MJ,Hawthorne KM,Voss JS,Kroneman TN,Famuyide AO,Clayton AC,Halling KC,Kerr SE,Cliby WA,Dowdy SC,Kipp BR,Mariani A,Oberg AL,Podratz KC,Shridhar V,Sherman ME

    更新日期：2015-04-01 00:00:00

  • Prognostic implication of endometriosis in clear cell carcinoma of the ovary.

    abstract：OBJECTIVE:The aim of this study is to investigate whether the presence of endometriosis is a prognostic factor in patients diagnosed with clear cell carcinoma (CCC) of the ovary. METHODS:Retrospective chart review was performed to all patients diagnosed with CCC and endometriosis between 1975 and 2002. All pathology r...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2008.05.025

    authors： Orezzoli JP,Russell AH,Oliva E,Del Carmen MG,Eichhorn J,Fuller AF

    更新日期：2008-09-01 00:00:00

  • Management of uterine adenosarcomas with and without sarcomatous overgrowth.

    abstract：OBJECTIVES:Uterine adenosarcomas (AS) are rare tumors composed of malignant stromal and benign epithelial components. We sought to evaluate the role of primary surgery, adjuvant treatments, and salvage therapies for patients with uterine adenosarcomas. METHODS:We identified all patients diagnosed with AS from 1990 to ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2012.12.036

    authors： Tanner EJ,Toussaint T,Leitao MM Jr,Hensley ML,Soslow RA,Gardner GJ,Jewell EL

    更新日期：2013-04-01 00:00:00

  • Quality of life in cervical cancer survivors: patient and provider perspectives on common complications of cervical cancer and treatment.

    abstract：OBJECTIVE:This study's objective was to quantify the impact (utility) of common complications of early cervical cancer treatment on quality of life (QOL). Utilities assigned by survivors were compared to those assigned by providers. METHODS:30 survivors of early cervical cancer identified from our Tumor Registry and 1...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2011.10.033

    authors： Einstein MH,Rash JK,Chappell RJ,Swietlik JM,Hollenberg JP,Connor JP

    更新日期：2012-04-01 00:00:00

  • Prognostic significance of an early decline in serum alpha-fetoprotein during chemotherapy for ovarian yolk sac tumors.

    abstract：BACKGROUND:The ovarian yolk sac tumor (OYST) is a very rare malignancy arising in young women. Our objective was to determine whether an early decline in serum alpha-fetoprotein (AFP) during chemotherapy has a prognostic impact. METHODS:This retrospective study is based on prospectively recorded OYST cases at Gustave ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2016.07.005

    authors： de la Motte Rouge T,Pautier P,Genestie C,Rey A,Gouy S,Leary A,Haie-Meder C,Kerbrat P,Culine S,Fizazi K,Lhommé C

    更新日期：2016-09-01 00:00:00

  • Update on novel therapeutic agents for cervical cancer.

    abstract：:Effective cytotoxic treatment options for advanced cervical cancer are exceedingly limited. Cisplatin-based combination chemotherapy, the most commonly used cytotoxic therapy, has produced response rates ranging from 20% to 30% and overall survival of less than 10 months. Because of the minimal degree of success with ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章,评审

    doi：10.1016/j.ygyno.2008.04.016

    authors： del Campo JM,Prat A,Gil-Moreno A,Pérez J,Parera M

    更新日期：2008-09-01 00:00:00

  • Risk factors for ovarian cancer in central Italy.

    abstract：OBJECTIVE:We conducted a case-control study to analyze risk factors for ovarian cancer. METHODS:Cases included 440 women (age range 13-80 years, median 54) with a histologically confirmed diagnosis of epithelial ovarian cancer who were admitted to the Gynecological Oncological Department of Gynecologic Oncology at the...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1006/gyno.2000.5909

    authors： Greggi S,Parazzini F,Paratore MP,Chatenoud L,Legge F,Mancuso S,La Vecchia C

    更新日期：2000-10-01 00:00:00

  • Use of V-Y flap for vulvar reconstruction.

    abstract：:Less extensive surgical treatment has become possible for limited vulvar cancer. However, primary closure is advisable only when the defect is minimal and tissue replacement is always needed in radical excisions. Local flaps are always considered the first choice because of their characteristics of similarity to the r...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1006/gyno.1996.0216

    authors： Tateo A,Tateo S,Bernasconi C,Zara C

    更新日期：1996-08-01 00:00:00

  • Treatment of cervical intraepithelial neoplasia with the carbon dioxide laser.

    abstract：:Between 1978 and 1983, one hundred and forty-six patients with CIN I-III were treated with the carbon dioxide laser and 129 have been followed for 6 to 58 months. The remission rate was 92.2% after one treatment and 98.4% after two treatments. All persistent lesions were detected within 8 weeks after treatment. After ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/0090-8258(85)90271-9

    authors： Tsukamoto N

    更新日期：1985-07-01 00:00:00

  • Simple extrafascial trachelectomy and pelvic bilateral lymphadenectomy in early stage cervical cancer.

    abstract：OBJECTIVE:To determine the feasibility and safety of simple extra-fascial trachelectomy plus pelvic lymphadenectomy in young patients affected by early stage cervical cancer. METHODS:We have prospectively identified all patients with early-stage cervical cancer (stages IA2-IB1) referred to our department. Inclusion cr...

    journal_title：Gynecologic oncology

    pub_type： 临床试验,杂志文章

    doi：10.1016/j.ygyno.2012.04.004

    authors： Palaia I,Musella A,Bellati F,Marchetti C,Di Donato V,Perniola G,Benedetti Panici P

    更新日期：2012-07-01 00:00:00

  • Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factors.

    abstract：OBJECTIVE:The aberrant expression of hepatocyte growth factor and its receptor c-Met are associated with aggressive disease and poor prognosis in a variety of human malignancies including ovarian cancer (OC). Specificity protein (Sp) transcription factors have high relevance in the signaling cascade associated with c-M...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2011.03.014

    authors： Basha R,Ingersoll SB,Sankpal UT,Ahmad S,Baker CH,Edwards JR,Holloway RW,Kaja S,Abdelrahim M

    更新日期：2011-07-01 00:00:00

  • Compliance with research standards within gynecologic oncology fellowship: A Gynecologic Oncology Fellowship Research Network (GOFRN) study.

    abstract：OBJECTIVES:Participation in clinical and basic science research is emphasized in gynecologic oncology training. We sought to identify trends in adherence to expected research practices and reasons for non-adherence among gynecologic oncology fellows. METHODS:An anonymous 31-question online survey assessing academic be...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2017.06.034

    authors： Moulton LJ,Michener CM,Levinson K,Cobb L,Tseng J,Jernigan A

    更新日期：2017-09-01 00:00:00

  • Pre-diagnosis body mass index, physical activity and ovarian cancer mortality.

    abstract：BACKGROUND:Ovarian cancer is the deadliest gynecologic malignancy, yet the effects on survival of modifiable pre-diagnosis lifestyle factors, such as obesity and physical activity, remain largely unexplored. Our objective was to evaluate the effect of pre-diagnosis BMI and physical activity on ovarian cancer mortality ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2019.07.025

    authors： Zamorano AS,Hagemann AR,Morrison L,Lee JA,Liao LM,Brinton LA,Park Y,Toriola AT

    更新日期：2019-10-01 00:00:00

  • Chemoradiation in locally advanced cervical carcinoma: an analysis of cisplatin dosing and other clinical prognostic factors.

    abstract：OBJECTIVES:The aim of this study was to evaluate the effect of number of chemotherapy cycles and other clinical and pathologic factors on progression-free (PFS) and overall survival (OS) in patients with newly diagnosed cervical cancer. METHODS:We identified 118 patients with locally advanced cervical cancer (stages I...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2009.09.045

    authors： Nugent EK,Case AS,Hoff JT,Zighelboim I,DeWitt LL,Trinkhaus K,Mutch DG,Thaker PH,Massad LS,Rader JS

    更新日期：2010-03-01 00:00:00

  • Radiotherapy with concurrent cisplatin-based doublet or weekly cisplatin for cervical cancer: a systematic review and meta-analysis.

    abstract：BACKGROUND:Treatment with weekly cisplatin (CDDP) plus radiotherapy (RT) is the standard regimen for stage IB to stage IVA cervical carcinoma (CC). We performed a systematic review and meta-analysis of published studies to evaluate whether CDDP-based doublet therapy improves survival compared to weekly CDDP plus RT in ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章,meta分析,评审

    doi：10.1016/j.ygyno.2014.04.049

    authors： Petrelli F,De Stefani A,Raspagliesi F,Lorusso D,Barni S

    更新日期：2014-07-01 00:00:00

  • Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: A Gynecologic Oncology Group study.

    abstract：OBJECTIVES:The objectives of this study were to assess efficacy and toxicity of the combination of bleomycin, etoposide, and cisplatin (BEP) in this Phase II trial as first-line therapy for ovarian stromal malignancies. METHODS:Patients with incompletely resected Stages II-IV or recurrent cancer underwent surgical deb...

    journal_title：Gynecologic oncology

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1006/gyno.1998.5304

    authors： Homesley HD,Bundy BN,Hurteau JA,Roth LM

    更新日期：1999-02-01 00:00:00

  • Reliability of frozen section examination in identifying poor prognostic indicators in stage I endometrial adenocarcinoma.

    abstract：:Management of Stage I adenocarcinoma of the uterus includes hysterectomy, bilateral salpingo-oophorectomy, and selective paraaortic and pelvic lymphadenectomy. Postoperative radiation therapy (RT) is selectively employed in patients with histologically defined poor prognostic indicators. We attempted to identify these...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/0090-8258(89)90162-5

    authors： Malviya VK,Deppe G,Malone JM Jr,Sundareson AS,Lawrence WD

    更新日期：1989-09-01 00:00:00

  • Supervised clustering of immunohistochemical markers to distinguish atypical endometrial hyperplasia from grade 1 endometrial cancer.

    abstract：OBJECTIVES:Differentiation between grade-1 endometrial cancer (EC) and atypical endometrial hyperplasia (AEH) is crucial to determine optimal surgical management. However, discrepancies exist between preoperative diagnosis of AEH and final histology. Our aim was to establish clusters of immunohistochemical markers to d...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2014.02.018

    authors： Laas E,Ballester M,Cortez A,Gonin J,Daraï E,Graesslin O

    更新日期：2014-05-01 00:00:00

  • Cytidine deaminase Apobec3a induction in fallopian epithelium after exposure to follicular fluid.

    abstract：OBJECTIVE:Ovarian carcinomas that originate from fallopian epithelial cells are suggested to arise due to repeated exposure to ovulatory follicular fluid (FF). Mechanistic explanation(s) for how this occurs are unknown. Here, we sought to understand if FF exposure to fallopian epithelial cells could induce DNA damage a...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2017.02.017

    authors： Brachova P,Alvarez NS,Van Voorhis BJ,Christenson LK

    更新日期：2017-06-01 00:00:00

  • Preferences for surveillance strategies for women treated for high-grade precancerous cervical lesions.

    abstract：OBJECTIVES:Data are lacking on how women view alternative approaches to surveillance for cervical cancer after treatment of high-grade cervical intraepithelial neoplasia. We measured and compared patient preferences (utilities) for scenarios with varying surveillance strategies and outcomes to inform guidelines and cos...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2010.05.002

    authors： Kuppermann M,Melnikow J,Slee C,Tancredi DJ,Kulasingam S,Birch S,Helms LJ,Bayoumi AM,Sawaya GF

    更新日期：2010-08-01 00:00:00

  • Photodynamic therapy using topically applied dihematoporphyrin ether in the treatment of cervical intraepithelial neoplasia.

    abstract：OBJECTIVE:To perform a phase I study of topically applied dihematoporphyrin ether (DHE) in the photodynamic treatment (PDT) of cervical intraepithelial neoplasia (CIN) using fixed DHE doses and application schedules, and a variable dose of 630 nm red light delivered by an argon-pumped dye laser. METHODS:Between Februa...

    journal_title：Gynecologic oncology

    pub_type： 临床试验,杂志文章

    doi：10.1006/gyno.1996.4463

    authors： Monk BJ,Brewer C,VanNostrand K,Berns MW,McCullough JL,Tadir Y,Manetta A

    更新日期：1997-01-01 00:00:00

  • A multicenter phase II study with triptorelin (sustained-release LHRH agonist) in advanced or recurrent endometrial carcinoma: a French anticancer federation study.

    abstract：:The objective of this phase II multicenter study was to assess the efficacy and tolerance of triptorelin (a sustained-release LHRH agonist) in advanced or recurrent endometrial cancer. A total of 101 monthly intramuscular injections were administered to 24 eligible patients (median number/patient = 3; range 1-12). Mai...

    journal_title：Gynecologic oncology

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1006/gyno.1999.5538

    authors： Lhommé C,Vennin P,Callet N,Lesimple T,Achard JL,Chauvergne J,Luporsi E,Chinet-Charrot P,Coudert B,Couette JE,Guastalla JP,Lebrun D,Ispas S,Blumberg J

    更新日期：1999-11-01 00:00:00

  • Comparison of neutropenia in a randomized, crossover trial of 3-, 6-, and 24-h infusions of paclitaxel.

    abstract：OBJECTIVE:Paclitaxel is most commonly infused over 3 hs rather than the original schedule of 24 h as the briefer infusion duration results in greater convenience, similar efficacy, significantly less myelosuppression, and less cost. While differences in toxicity between 3- and 24-h infusions are well described, there i...

    journal_title：Gynecologic oncology

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1016/s0090-8258(03)00459-1

    authors： Jennens R,Rischin D,Yuen K,Toner G,Millward M

    更新日期：2003-10-01 00:00:00

  • Therapy-related myeloid leukemia after treatment for epithelial ovarian carcinoma: an epidemiological analysis.

    abstract：OBJECTIVE:Therapy related acute myeloid leukemia (t-AML) is a potential late complication of cytotoxic therapy, and it is of particular concern in the treatment of patients with epithelial ovarian carcinoma (EOC) exposed to multiple courses of chemotherapy during the course of their disease. This study examines the inc...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2011.07.097

    authors： Vay A,Kumar S,Seward S,Semaan A,Schiffer CA,Munkarah AR,Morris RT

    更新日期：2011-12-01 00:00:00

  • Recurrent and persistent squamous cell cervical carcinoma in women under age 35.

    abstract：:Forty-five patients with invasive cervical squamous cell carcinoma were registered in the Tom Baker Cancer Centre from 1980 to 1985. The natural history of 22 patients (48.9%) who developed persistent or recurrent disease including 11 Stage IB, 8 Stage IIB, and 3 Stage IIIB is reported. Only one patient who had the un...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/0090-8258(88)90020-0

    authors： Stuart GC,Robertson DI,Fedorkow DM,Duggan MA,Nation JG

    更新日期：1988-06-01 00:00:00

  • Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion.

    abstract：OBJECTIVES:Endometrioid adenocarcinoma of the endometrium (EEC) is the most common histologic type of endometrial cancer, with stage being the most critical prognostic factor. Cervical involvement (CI), divided into IIA (epithelial involvement) and IIB (stromal invasion), is overall associated with decreased survival (...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2009.03.007

    authors： Orezzoli JP,Sioletic S,Olawaiye A,Oliva E,del Carmen MG

    更新日期：2009-06-01 00:00:00

  • Mutations in TAP genes are common in cervical carcinomas.

    abstract：OBJECTIVE:To determine whether squamous cervical cancers exhibit mutations or deletions in MHC class I genes or transport-associated protein (TAP) genes. METHODS:Polymerase chain reaction based protocols were used to examine HLA class I and TAP genes in a panel of cervical tumours, using DNA from corresponding blood s...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2003.11.037

    authors： Fowler NL,Frazer IH

    更新日期：2004-03-01 00:00:00

  • Human papillomavirus genotype distribution in cervical cancer cases in Spain. Implications for prevention.

    abstract：OBJECTIVE:Human papillomavirus (HPV) genotype distribution in invasive cervical cancer (ICC) is critical to guide the introduction and to assess the impact of HPV prophylactic vaccines. This study aims to provide specific information for Spain. METHODS:1043 histological confirmed ICC cases diagnosed from 1940 to 2007 ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.ygyno.2011.11.024

    authors： Alemany L,Pérez C,Tous S,Llombart-Bosch A,Lloveras B,Lerma E,Guarch R,Andújar M,Pelayo A,Alejo M,Ordi J,Klaustermeier J,Velasco J,Guimerà N,Clavero O,Castellsagué X,Quint W,Muñoz N,Bosch FX,de Sanjosé S,Spanish st

    更新日期：2012-03-01 00:00:00

  • Implicit bias toward cervical cancer: Provider and training differences.

    abstract：OBJECTIVE:Implicit prejudice and stereotyping may exist in health care providers automatically without their awareness. These biases can correlate with outcomes that are consequential for the patient. This study examined gynecologic oncology care providers' implicit prejudice and stereotyping toward cervical cancer. M...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2019.01.013

    authors： Liang J,Wolsiefer K,Zestcott CA,Chase D,Stone J

    更新日期：2019-04-01 00:00:00

  • Adriamycin and cis-diamminedichloroplatinum in the treatment of metastatic endometrial adenocarcinoma.

    abstract：:Adriamycin (50 mg/m2) and cis-diamminedichloroplatinum (50 mg/m2) were administered every 21 days to treat metastatic endometrial adenocarcinoma. This regimen resulted in three responses (one complete and two partial) in nine women (33%). Most patients had moderate or severe hematologic and gastrointestinal toxicity. ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/0090-8258(84)90197-5

    authors： Seltzer V,Vogl SE,Kaplan BH

    更新日期：1984-11-01 00:00:00